Hepatobiliary Cancer Coverage from Every Angle

Available Clinical Trials

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study of Multiple Immunotherapy-Based Treatment Combinations in Advanced Liver Cancers
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor, Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-Line Therapy
A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
ALTUS: Performance of a Multitarget Hepatocellular Carcinoma Test in Subjects With Increased Risk
Atezolizumab in Combination With a Multikinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
Is Chemotherapy, Bevazicumab, and Atezolizumab Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer?
Liver Cancer Disparities in American Indian and Alaska Native Persons
Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2)
Phase III Study of Toripalimab (JS001) Combined With Lenvatinib for Advanced HCC
Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Study of Pembrolizumab and Olaparib in Bile Duct Cancer
Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.